Skip to main content
SpringerLink
Log in

Left ventricular hypertrophy: Unresolved issues

  • Clinical Trials Review
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Conclusions

The proposition that reduction in LV mass confirms clinical benefit will require properly designed prospective clinica trials. These studies must resolve the issue of what is the best drug regimen, and what is the role of reduction of bloo pressure and LV mass to reduction in cardiovascular morbidity and mortality. If possible, studies should attempt t explain the paradoxical rise in congestive heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ghali JK, Liao Y, Summons B, et al.: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992, 117:831–836.

    PubMed  CAS  Google Scholar 

  2. Levy D, Anderson KM, Savage DD, et al.: Echocardiographically detected left ventricular hypertrophy: prevalenc and risk factors. The Framingham Heart Study. Ann Intern Med 1988, 108:7–13.

    PubMed  CAS  Google Scholar 

  3. Gottdiener JS, Reds DJ, Materson BJ, et al.: Importance of obesity, race, and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994, 24:1492–1498.

    Article  PubMed  CAS  Google Scholar 

  4. Liebson PR: Clinical studies of drug reversal of hypertensive left ventricular hypertrophy. Am J Hypertens 1990, 3:512–517.

    PubMed  CAS  Google Scholar 

  5. Tremarco B, Wikstrand J: Regression of cardiovascular structural changes by anti-hypertensive treatment: functional consequences and time course of reversal as judged from clinical studies. Hypertension 1984, 6(suppl 3):111–150.

    Google Scholar 

  6. Gottdiener JS: Clinical trials of single-drug therapy for the cardiac effects of hypertension [review]. Am J Hypertens 1999, 12(pt 2):12S-18S.

    Article  PubMed  CAS  Google Scholar 

  7. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analyses of 109 treatment studies. Am J Hypertens 1992, 5:95–110.

    PubMed  CAS  Google Scholar 

  8. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a metaanalysis of randomized double-blind studies. JAMA 1996, 275:1507–1513.

    Article  PubMed  CAS  Google Scholar 

  9. Liebson PR, Grandets GA, Dianzumba S, et al.: Comparison of five antihypertensive mono-therapies and placebo for change in left ventricular mass in patients receiving mutulionalhygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995, 91:698–706.

    PubMed  CAS  Google Scholar 

  10. Materson BJ, Rede DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men: comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents N Engl J Med 1993, 328:914–921.

    Article  PubMed  CAS  Google Scholar 

  11. Khatri IM, Gottdrener JS, Notargiacomo AV, Freis E: The effect of therapy on left ventricular function. Clin Sci 1980, 59:435S-439S.

    PubMed  CAS  Google Scholar 

  12. Aurigemma G, Gotthiner J, Gaasch W, et al.: Ventricular and myocardial function following regression of hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995, 27:215A.

    Google Scholar 

  13. Tremarco B, DeLuca N, Rosiello G: Improvement of diastolic function after reversal of left ventricular hypertrophy induced by long-term antihypertensive treatment with tetralolol. Am J Cardiol 1989, 64:745–751.

    Article  Google Scholar 

  14. Levy D, Solomon M, D’Agnostino RB, et al.: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90:1786–1793.

    PubMed  CAS  Google Scholar 

  15. Muiesan ML, Salvetti M, Rizzoni D, et al.: Association of changes in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995, 13:1091–1095.

    Article  PubMed  CAS  Google Scholar 

  16. Verdecchia P, Schellace G, Bongioni C, et al.: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48–54.

    PubMed  CAS  Google Scholar 

  17. Mosterd A, D’Agnostino RB, Silbershatz H, et al.: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999, 340:1221–1227.

    Article  PubMed  CAS  Google Scholar 

  18. Senni M, Tribouilloy CM, Rodeheffer RJ, et al.: Congestive heart failure in the community: trends in increase and survival in a 10-year period. Arch Intern Med 1998, 59:29–34.

    Google Scholar 

  19. Trend shift among heart failure patients. Clinician Reviews 1997, 7:155–156.

Download references

Author information

Authors and Affiliations

  1. 17501 Los Eucalyptos, PO Box 1514, 92067, Rancho Sante Fe, CA, USA

    James A. Schoenberger MD

Authors
  1. James A. Schoenberger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schoenberger, J.A. Left ventricular hypertrophy: Unresolved issues. Current Science Inc 1, 331–332 (1999). https://doi.org/10.1007/s11906-999-0041-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0041-6

Keywords

Search

Navigation